Literature DB >> 23264664

Correlation between the administration of morphine or oxycodone and the development of infections in patients with cancer pain.

Miharu Suzuki1, Tomoya Sakurada, Kazumi Gotoh, Satoshi Watanabe, Nobunori Satoh.   

Abstract

Morphine and oxycodone are widely used in the therapy for cancer pain. Although some previous studies have reported that morphine induces immunosuppression and oxycodone does not, whether this is true for human infections is unclear. We performed a retrospective study on the correlation between the administration of morphine or oxycodone and the development of infections in patients with cancer pain. This study was undertaken in 841 inpatients receiving only 1 opioid continuously for more than 10 days. Development of infections was based on (1) antibiotic administration and (2) diagnosis of infections, positive microbial culture test, or increase in white blood cells or C-reactive protein. Liver, kidney, and hematological cancer, antineoplastic drugs, radiotherapy, steroid, immunosuppressive agents, granulocyte colony-stimulating factor, and thyroid inhibitors were defined as the exclusion criteria in consideration of influence on immune system or metabolism and excretion of morphine and oxycodone. A total of 60 morphine and 74 oxycodone cases were included, which resulted in 18 and 10 infection cases. Significantly more patients treated with morphine developed infections than those patients treated with oxycodone (odds ratio = 3.60, 95% confidence interval = 1.40-9.26). No significant differences were seen in the other variables analyzed. Although perhaps some confounding variables were included because this was an observational rather than randomized study, these results suggested that morphine's immunosuppressive effect may contribute to the development of infections in patients with cancer pain.

Entities:  

Keywords:  cancer pain; immunosuppression; infection; morphine; opioid; oxycodone

Mesh:

Substances:

Year:  2012        PMID: 23264664     DOI: 10.1177/1049909112469823

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  7 in total

Review 1.  Influence of opioids on immune function in patients with cancer pain: from bench to bedside.

Authors:  Jason W Boland; A Graham Pockley
Journal:  Br J Pharmacol       Date:  2017-07-23       Impact factor: 8.739

Review 2.  Chronic opioid therapy in long-term cancer survivors.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2016-07-21       Impact factor: 3.405

Review 3.  Do All Opioid Drugs Share the Same Immunomodulatory Properties? A Review From Animal and Human Studies.

Authors:  Silvia Franchi; Giorgia Moschetti; Giada Amodeo; Paola Sacerdote
Journal:  Front Immunol       Date:  2019-12-12       Impact factor: 7.561

4.  Effects of transcutaneous electrical acupoint stimulation on perioperative immune function and postoperative analgesia in patients undergoing radical mastectomy: A randomized controlled trial.

Authors:  Li Ao; Jinlin Shi; Yaowu Bai; Shan Zhang; Jianhui Gan
Journal:  Exp Ther Med       Date:  2021-01-07       Impact factor: 2.447

Review 5.  Less Well-Known Consequences of the Long-Term Use of Opioid Analgesics: A Comprehensive Literature Review.

Authors:  Aleksandra Kotlińska-Lemieszek; Zbigniew Żylicz
Journal:  Drug Des Devel Ther       Date:  2022-01-18       Impact factor: 4.162

6.  Comparison of oxycodone and morphine on the proliferation, apoptosis and expression of related molecules in the A549 human lung adenocarcinoma cell line.

Authors:  Mi Tian; Li Jin; Renqi Li; Sihai Zhu; Muhuo Ji; Weiyan Li
Journal:  Exp Ther Med       Date:  2016-05-17       Impact factor: 2.447

Review 7.  Opioids in Cancer Development, Progression and Metastasis: Focus on Colorectal Cancer.

Authors:  Adrian Szczepaniak; Jakub Fichna; Marta Zielińska
Journal:  Curr Treat Options Oncol       Date:  2020-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.